No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers

Gynecologic Oncology

Volumn 95, Issue 3, 2004, Pages 430-436

  Aghmesheh, Morteza ^a,b,c   Nesland, Jahn M ^d   Kaern, Janne ^d   Dorum, Anne ^d   Edwards, Lyndal ^a   Byth, Karen ^e   Friedlander, Michael ^a,b,c   Jackson, Paul ^a,b   Tucker, Katherine M ^a,b,c   Russell, Pamela J ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Kathleen Cuningham Consortium R ^*  (United States)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Check point; Environmental factor; Modifier gene

Indexed keywords

BRCA1 PROTEIN; PROTEIN P53;

ARTICLE; AUSTRALIA; CANCER GRADING; CANCER STAGING; CELL CYCLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEASUREMENT; MUTATION RATE; NORWAY; OVARY CANCER; PENETRANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLE; SOMATIC MUTATION; STATISTICAL SIGNIFICANCE;

ADULT; AGED; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, BRCA1; GENES, P53; GERM-LINE MUTATION; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION, MISSENSE; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 9944224747     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.08.035     Document Type: Article

References (43)

1. S.A. Narod Genetics of breast and ovarian cancer Br. Med. Bull. 50 3 1994 656 676
2. D. Ford, D.F. Easton, M. Stratton, S. Narod, D. Goldgar, and P. Devilee Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium Am. J. Hum. Genet. 62 3 1998 676 689
3. M. Schuyer, and E.M.J.J. Berns Is Tp53 dysfunction required for BRCA1-associated carcinogenesis? Mol. Cell. Endocrinol. 155 1999 143 152
4. H. Zhang, K. Somasundaram, Y. Peng, H. Tian, D. Ke Bi, and B.L. Weber BRCA1 physically associates with p53 and stimulates its transcriptional activity Oncogene 16 1998 1713 1721
5. G. Eiriksdottir, R.B. Barkardottir, B.A. Agnarsson, G. Johannesdottir, K. Olafsdottir, and V. Egilsson High incidence of loss of heterozygosity at chromosome 17p13 in breast tumors from BRCA2 mutation carriers Oncogene 16 1998 21 26
6. H. Lee, A.H. Trainer, L.S. Friedman, F.C. Thistlethwaite, M.J. Evans, and B.A.J. Ponder Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, BRCA2 Mol. Cell 4 1999 1 10
7. S.J. Ramus, L.G. Bobrow, P.D.P. Pharoah, D.S. Finnigan, A. Fishman, and M. Altaras Increased frequency of tp53 mutations in BRCA1 and BRCA2 ovarian tumors Genes Chromosomes Cancer 25 1999 91 96
8. R.E. Buller, T.A. Lallas, M.S. Shahin, A.K. Sood, M. Hatterman-Zogg, and B. Anderson The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer Clin. Cancer Res. 7 2001 831 838
9. waf1/cip1 Nature 389 6647 1997 187 190
10. T. Ouchi, A.N.A. Monteiro, A. August, and S.A. Aaronson BRCA1 regulates p53-dependent gene expression Proc. Natl. Acad. Sci. U. S. A. 95 1998 2302 2306
11. waf1/cip1 promoter Oncogene 18 1999 263 268
12. P.L. Welcsh, K.N. Owens, and M. King Insights into the functions of BRCA1 and BRCA2 TIG 16 2 2000 69 74
13. S.L. Rose, and R.E. Buller The role of p53 mutation in BRCA1-associated ovarian cancer Minerva Ginecol. 54 3 2002 201 209
14. A. Auranen, S. Grenman, and P.J. Klemi Immunohistochemically detected p53 and her-2/neu expression and nuclear DNA content in familial epithelial ovarian carcinomas Cancer 79 11 1997 2147 2153
15. A. Berchuck, and M. Carney Human ovarian cancer of the surface epithelium Biochem. Pharmacol. 54 1997 541 544
16. J. Diebold Molecular genetics of ovarian carcinomas Histol. Histopathol. 14 1999 269 277
17. O.T. Johannsson, I. Idvall, C. Anderson, A. Borg, R.B. Barkardottir, and V. Egilsson Tumor biological features of BRCA1-induced breast and ovarian cancer Eur. J. Cancer 33 3 1997 362 371
18. C.N. Otis, P.A. Krebs, M.M. Quezado, A. Albuquerque, X.S. Juan, and B. Bryant Loss of heterozygosity in p53, BRCA1, and estrogen receptor genes and correlation to expression of p53 protein in ovarian epithelial tumors of different cell types and biological behavior Hum. Pathol. 31 2 2000 233 238
19. E. Rhei, F. Bogomolniy, M.G. Federici, D.L. Maresco, K. Offit, and M.E. Robson Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers Cancer Res. 58 1998 3193 3196
20. W. Wen, A. Reles, I.B. Runnebaum, J. Sullivan-Halley, L. Bernstein, and L.A. Jones P53 mutations and expression in ovarian cancers: correlation with overall survival Int. J. Gynecol. Pathol. 18 1999 29 41
21. R.P. Zweemer, P.A. Shaw, R.M.H. Verheijen, A. Ryan, A. Berchuck, and B.A.J. Ponder Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations J. Clin. Pathol. 52 1999 372 375
22. M.S. Greenblatt, P.O. Chappuis, J.P. Bond, N. Hamel, and W.D. Foulkes Tp53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution Cancer Res. 61 2001 4092 4097
23. P.P. Osin, and S.R. Lakhani The pathology of familial breast cancer immunohistochemistry and molecular analysis Breast Cancer Res. 1 1 1999 36 40
24. G. Casey, M.E. Lopez, J.C. Ramos, S.J. Plummer, M.J. Arboleda, and M. Shaughnessy DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies Oncogene 13 9 1996 1971 1981
25. S. Sjogren, M. Inganas, T. Norberg, A. Lindgren, H. Nordgren, and L. Holmberg The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry J. Natl. Cancer Inst. 88 3-4 1996 173 182
26. M.F. Kohler, B.J. Kerns, P.A. Humphrey, J.R. Marks, R.C. Bast, and A. Berchuck Mutation and overexpression of p53 in early-stage epithelial ovarian cancer Obstet. Gynecol. 81 5 1993 643 650
27. M.F. Kohler, J.R. Marks, R.W. Wiseman, I.J. Jacobs, A.M. Davidoff, and D.L. Clarke-Pearson Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer J. Natl. Cancer Inst. 85 18 1993 1513 1519
28. A. Dorum, P. Moller, E.J. Kamsteeg, H. Scheffer, M. Burton, and K.R. Heimdal A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing Eur. J. Cancer 33 14 1997 2390 2392
29. A. Dorum, E. Hovig, C. Trope, M. Inganas, and P. Moller Three percent of Norwegian ovarian cancers are caused by BRCA1 1675delA or 1135insA Eur. J. Cancer 35 5 1999 779 781
30. A. Dorum, K. Heimdal, E. Hovig, M. Inganas, and P. Moller Penetrances of BRCA1 1675delA with respect to breast cancer and ovarian cancer Am. J. Hum. Genet. 65 1999 671 679
31. J.L. Yang, K.T. Ow, P.J. Russell, J.M. Ham, and P.J. Crowe Higher expression of oncoproteins c-myc, c-erbB-2/neu, PCNA, and p53 in metastasizing colorectal cancer than in nonmetastasizing tumors Ann. Surg. Oncol. 3 6 1996 574 579
32. A.M.F. Stapleton, T.L. Timme, A.E. Gousse, Q.F. Li, A.A. Tobon, and M.W. Kattan Primary human prostate cancer cells harboring p53 mutations are clonally expanded in metastases Clin. Cancer Res. 3 8 1997 1389 1397
33. T. Crook, S. Crossland, M.R. Crompton, P. Osin, and B.A. Gusterson P53 mutations in BRCA1-associated familial breast cancer Lancet 350 1997 638 639
34. R.P. Zweemer, R.H.M. Verheijen, J.J.P. Gille, P.J.V. Diest, G. Pals, and F.H. Menko Clinical and genetic evaluation of thirty ovarian cancer families Am. J. Obstet. Gynecol. 178 1 1998 85 90
35. R.E. Buller, M.S. Shahin, J.P. Geisler, M. Zogg, B.R. De Young, and C.S. Davis Failure of BRCA1 dysfunction to alter ovarian cancer survival Clin. Cancer Res. 8 5 2002 1196 1202
36. A.A. Jazaeri, C.J. Yee, C. Sotiriou, K.R. Brantley, J. Boyd, and E.T. Liu Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers J. Natl. Cancer Inst. 94 13 2002 990 1000
37. J.F. Stratton, C.H. Buckley, D. Lowe, B.A.J. Ponder, and UKCCCR Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation J. Natl. Cancer Inst. 91 7 1999 626 628
38. D.I. Quinn, S.M. Henshall, D.R. Head, D. Golovsky, J.D. Wilson, and P.C. Brenner Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy Cancer Res. 60 6 2000 1585 1594
39. M.M. Quezado, C.A. Moskaluk, B. Bryant, S.E. Mills, and M.J. Merino Incidence of loss of heterozygosity at p53 and BRCA1 loci in serous surface carcinoma Hum. Pathol. 30 2 1999 203 207
40. A. Berchuck, K-A. Heron, M.E. Carney, J.M. Lancaster, E.G. Fraser, and V.L. Vinson Frequency of germline and somatic BRCA1 mutations in ovarian cancer Clin. Cancer Res. 4 10 1998 2433 2437
41. T.A. Lallas, T.E. Buekers, and R.E. Buller BRCA1 mutations in familial ovarian cancer Mol. Genet. Metab. 67 4 1999 357 363
42. S.D. Merajver, T.M. Pham, R.F. Caduff, M. Chen, E.L. Poy, and K.A. Cooney Somatic mutations in the BRCA1 gene in sporadic ovarian tumors Nat. Genet. 9 4 1995 439 443
43. J.L. Bernstein, W.D. Thompson, G. Casey, R.A. DiCioccio, A.S. Whittemore, and A.T. Diep Comparison of techniques for the successful detection of BRCA1 mutations in fixed paraffin-embedded tissue Cancer Epidemiol. Biomark. Prev. 11 9 2002 809 814